{"filing":{"accession_number":"0001079973-26-000855","cik":"0001128189","ticker":"PKTX","company_name":"ProtoKinetix, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"pktx_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/pktx_8k.htm"},"events":[{"id":11661,"run_id":10245,"accession_number":"0001079973-26-000855","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"ProtoKinetix appointed three individuals as directors on June 17, 2026, with Keith Brunt also appointed as president of the Company. Brunt's elevation to president represents a material executive role change, with extensive biographical detail provided on his qualifications.","company_name":"ProtoKinetix, Inc.","ticker":"PKTX","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8307,"accession_number":"0001079973-26-000855","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of three individuals as directors on June 17, 2026, with Keith Brunt also appointed as president of the Company. While Edward McDonough's resignation is mentioned, the principal disclosed actions center on the three new appointments, particularly Brunt's elevation to president—a material executive role change. The filing provides extensive biographical detail on Brunt's qualifications, signaling the materiality of his appointment to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:30:09.006113+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":11662,"run_id":10245,"accession_number":"0001079973-26-000855","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"ProtoKinetix formed a subsidiary (SightPath Biotech LLC) to develop PKX-001 for dry-eye disease with patents valued at approximately $253 million, disclosed late filings of its 2025 10-K and 2026 Q1 10-Q, and repriced 61.19 million options and 6 million warrants downward from $0.028 to $0.01 per share with extended expiration dates. The combination of subsidiary formation with substantial IP valuation, filing delays, and significant dilutive equity repricing reflects material corporate restructuring and financial stress.","company_name":"ProtoKinetix, Inc.","ticker":"PKTX","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8308,"accession_number":"0001079973-26-000855","item_number":"8.01","item_title":"Other Items.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This Item 8.01 disclosure contains multiple material events: (1) formation of a subsidiary (SightPath Biotech LLC) to develop PKX-001 for dry-eye disease with patents valued at ~$253 million based on independent valuations; (2) late filings of the 2025 10-K and 2026 Q1 10-Q, signaling potential financial reporting delays; and (3) repricing of 61.19 million options and 6 million warrants downward from $0.028 to $0.01 per share with extended expiration dates. The combination of subsidiary formation with substantial IP valuation, filing delays, and significant dilutive equity repricing reflects material corporate restructuring and financial stress that would affect a reasonable investor's assessment, but does not fit cleanly into a single taxonomy category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:30:09.006113+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8307,"accession_number":"0001079973-26-000855","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of three individuals as directors on June 17, 2026, with Keith Brunt also appointed as president of the Company. While Edward McDonough's resignation is mentioned, the principal disclosed actions center on the three new appointments, particularly Brunt's elevation to president—a material executive role change. The filing provides extensive biographical detail on Brunt's qualifications, signaling the materiality of his appointment to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:30:09.006113+00:00","company_name":"ProtoKinetix, Inc.","ticker":"PKTX","filing_date":"2026-06-17"},{"id":8308,"accession_number":"0001079973-26-000855","item_number":"8.01","item_title":"Other Items.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This Item 8.01 disclosure contains multiple material events: (1) formation of a subsidiary (SightPath Biotech LLC) to develop PKX-001 for dry-eye disease with patents valued at ~$253 million based on independent valuations; (2) late filings of the 2025 10-K and 2026 Q1 10-Q, signaling potential financial reporting delays; and (3) repricing of 61.19 million options and 6 million warrants downward from $0.028 to $0.01 per share with extended expiration dates. The combination of subsidiary formation with substantial IP valuation, filing delays, and significant dilutive equity repricing reflects material corporate restructuring and financial stress that would affect a reasonable investor's assessment, but does not fit cleanly into a single taxonomy category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:30:09.006113+00:00","company_name":"ProtoKinetix, Inc.","ticker":"PKTX","filing_date":"2026-06-17"}]}